During the past decade, The Dana-Farber Cancer Institute at Londonderry conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 18 clinical trials were completed, i.e. on average, 72% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 14 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Dana-Farber Cancer Institute at Londonderry" #1 sponsor was "Dana-Farber Cancer Institute" with 16 trials, followed by "Alliance for Clinical Trials in Oncology" with 10 trials sponsored, "National Cancer Institute (NCI)" with 9 trials sponsored, "Alliance Foundation Trials, LLC." with 1 trials sponsored and "Canadian Cancer Trials Group" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Dana-Farber Cancer Institute at Londonderry" #1 collaborator was "National Cancer Institute (NCI)" with 12 trials as a collaborator, "Canadian Cancer Trials Group" with 2 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "Pfizer" with 2 trials as a collaborator and "Ambry Genetics" with 1 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "The Dana-Farber Cancer Institute at Londonderry" are "Breast Cancer" (13 trials), "Stage IB Lung Non-Small Cell Carcinoma AJCC v7" (3 trials), "Stage II Lung Non-Small Cell Cancer AJCC v7" (3 trials), "Stage IIIA Lung Non-Small Cell Cancer AJCC v7" (3 trials) and "Breast Ductal Carcinoma In Situ" (2 trials). Many other conditions were trialed in "The Dana-Farber Cancer Institute at Londonderry" in a lesser frequency.

Most popular intervention types in "The Dana-Farber Cancer Institute at Londonderry" are "Drug" (29 trials), "Other" (20 trials), "Biological" (7 trials), "Dietary Supplement" (3 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (7 trials), "Paclitaxel" (6 trials), "Quality-of-Life Assessment" (6 trials), "Questionnaire Administration" (5 trials) and "Clinical Observation" (4 trials). Other intervention names were less common.

The vast majority of trials in "The Dana-Farber Cancer Institute at Londonderry" are 30 trials for "All" genders, 7 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "The Dana-Farber Cancer Institute at Londonderry". undefined are not yet recruiting, 9 are recruiting, 15 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in The Dana-Farber Cancer Institute at Londonderry, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in The Dana-Farber Cancer Institute at Londonderry, 0 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 5 trials that are defined as “Not Applicable".